Telix Pharmaceuticals (ASX:TLX) said that its Phase 2 IPAX-Linz study of drug candidate TLX101, in combination with external beam radiation therapy (EBRT), was well tolerated and showed no serious adverse events in patients with brain cancer, according to a Wednesday filing with the Australian bourse.
The study indicated a median overall survival of 12.4 months from treatment initiation, and 32.2 months from diagnosis, the company said.
The company has submitted an ethics approval request for a registration-enabling study of TLX101 in recurrent brain cancer, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.